Editorial
Letter from the Editor-in-Chief

Dear Colleagues,



This issue of the Journal of Contemporary Brachytherapy consist of two parts: the first contains prepared manuscripts and the second – materials from “2011 Central Europe Users Meeting”, organizing by Nucletron, which will be held in Bratislava, Slovakia, 13-15 October 2011. Once again we publish materials from a scientific convention. We are open for a cooperation with any scientific society, a research team or a company which patronize a scientific meetings. You are most welcome to cooperate. Publishing of this materials does not mean in any matter a company preference.

In last year the Editorial Office along with the Publisher continued the process of indexing JCB. Now the Journal is indexed in Scopus, Index Copernicus, EMBASE (Excerpta Medica), Polish Medical Library (GBL), Directory of Open Access Journals (DOAJ), ProQuest base. And we are still waiting for answer from Index Medicus/MEDLINE and PubMed. Next planned index are indexes from so called Philadelphia list. In order to achieve next steps, we urgently require good, original papers of international origin and numerous citations in other papers. Please cite JCB articles in your papers. Not only clinical papers but also review papers, case reports, technical notes are welcome.

Seven manuscripts are published in this issue - three clinical concerning prostate cancer, physics and biological contributions concerning gyneacological cancers and breast cancer and one case report of iris melanoma. Presented articles enclose results of clinical researches as well as physicists papers. Every paper has been carefully reviewed, however we are perfectly aware that some mistakes could be found. We are happy that more and more of our colleagues agrees to review and to publish their papers in our Journal.

And finally some news from brachytherapy. Elekta AB announced on 15th October has successfully completed its acquisition of Nucletron, the world leader in brachytherapy treatment planning and delivery. Through the combination Elekta will offer a complete range of radiotherapy planning and delivery technologies. As the market leader in Europe and with strong positions in North America and Asia, Elekta will enhance the combined ability to meet the clinical needs of cancer patients and health care providers throughout the world. "Now we have successfully completed the acquisition and we are very enthusiastic about...


View full text...